Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • April 27, 2025

Jaiswal V, Hanif M, Mashkoor Y, Prasad T, Fonarow GC. Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2025 Apr 14;4(5):101696. doi: 10.1016/j.jacadv.2025.101696. Epub ahead of print. PMID: 40286362.

Tags: Cardiology/Epi, Publications

Related Posts

FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494

Holzgreve A, Unterrainer LM, Flores K, Lam EC, Mona CE, Czernin J, Shuch BM, Sisk AE Jr, Calais J. FAP Expression in Renal Tumors Assessed[...]

Akebia Saponin D Targeting Ubiquitin Carboxyl-Terminal Hydrolase 4 Promotes Peroxisome Proliferator-Activated Receptor Gamma Deubiquitination and Activation of Brown Adipose Tissue Thermogenesis in Obesity

Chen L, Liu DH, Li YX, Yang S, Jia WH, Peng L, Liu HL, Wang XB, Hu B, Wang YC, Pan C, Lusis AJ, Liu[...]

The relationship between blood eosinophil count and cardiovascular outcomes in prediabetes and diabetes patients with acute coronary syndrome: insights from a large Asian cohort analysis

Feng X, Liu Y, Qin H, Zhao S, Yang J, Yang S, Zhou Z, Liu Y, Wang Z, Shi D, Zhou Y, Guo Q. The[...]